SNORD90: A Potential Drug Target and Biomarker (G692206)

Target Name: SNORD90

NCBI ID: G692206

SNORD90

Other Name(s): small nucleolar RNA, C/D box 90 | HBII-295 | Small nucleolar RNA, C/D box 90

SNORD90: A Potential Drug Target and Biomarker

Small nucleolar RNA (snRNA) is a non-coding RNA molecule that plays a crucial role in the regulation of gene expression in eukaryotic cells. One of the most well-known snRNAs is SNORD90, which is located in the C/D box region and is responsible for the maintenance of mRNA stability. SNORD90 has been identified as a potential drug target and biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The C/D box region of SNORD90 is a unique feature that gives it a specific structure and function. This region contains a conserved core that is involved in the formation of a double helix, as well as a unique loop region that is involved in the regulation of mRNA stability. The double helix in the C/D box region functions as a stability factor, while the loop region interacts with the 5'-end of the mRNA. This interaction between the C/D box and the 5'-end region allows SNORD90 to regulate the stability of mRNAs, which is essential for the proper function of gene expression.

SNORD90 has been shown to play a role in the regulation of various cellular processes, including cell growth, apoptosis, and autophagy. It has been shown to interact with several cellular signaling pathways, including the TGF-β pathway, the PI3K/Akt pathway, and the NF-kappa-B pathway.

In addition to its role in cellular signaling, SNORD90 has also been shown to be involved in the development and progression of several diseases. For example, SNORD90 has been shown to be overexpressed in various cancer types, including breast, ovarian, and colorectal cancer. This overexpression is associated with poor prognosis and increased disease severity.

Furthermore, SNORD90 has also been shown to be involved in the regulation of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles, which are thought to be caused by the misfolding of SNORD90 and other snRNAs.

SNORD90 has also been shown to be involved in the regulation of autoimmune diseases, including rheumatoid arthritis and multiple sclerosis. These conditions are characterized by the production of autoantibodies and the destruction of the immune system's own cells.

In conclusion, SNORD90 is a unique and highly conserved snRNA that plays a critical role in the regulation of gene expression in eukaryotic cells. Its role in the regulation of cellular processes, including cell growth, apoptosis, and autophagy, as well as its involvement in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders make it an attractive drug target and biomarker. Further research is needed to fully understand the mechanisms of SNORD90's role in these diseases and to develop effective treatments.

Protein Name: Small Nucleolar RNA, C/D Box 90

The "SNORD90 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD90 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets